<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04165642</url>
  </required_header>
  <id_info>
    <org_study_id>Paroxysmal or persistent AF</org_study_id>
    <nct_id>NCT04165642</nct_id>
  </id_info>
  <brief_title>Single-Laser PVI: Single-encirclement Laserballoon Ablation for Pulmonary Veins Isolation</brief_title>
  <acronym>SingleLaserPVI</acronym>
  <official_title>Single-Laser PVI: Single-encirclement Laserballoon Ablation for Pulmonary Veins Isolation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>IRCCS Policlinico S. Donato</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>IRCCS Policlinico S. Donato</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To assess the efficacy of laser balloon ablation of atrial fibrillation (AF) without&#xD;
      verification of electrical isolation of pulmonary veins using implantable loop recorder.&#xD;
&#xD;
      This is a prospective and single-center study. A targeted number of 82 patients suffering&#xD;
      from paroxysmal or persistent AF, indicated to undergo catheter ablation will be included.&#xD;
      The study will consist of: i) patient enrolment, ii) treatment phase, and iii) 1-year&#xD;
      follow-up phase. The duration of the study is expected to be 24 months, from first patient&#xD;
      enrolment to last patient follow up.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a prospective and single-center study. A targeted number of 82 patients suffering&#xD;
      from paroxysmal or persistent AF, indicated to undergo catheter ablation will be included.&#xD;
      The study will consist of: i) patient enrolment, ii) treatment phase, and iii) 1-year&#xD;
      follow-up phase. The duration of the study is expected to be 24 months, from first patient&#xD;
      enrolment to last patient follow up.&#xD;
&#xD;
      In a recent meta-analysis including 1188 patients, free from arrhythmic recurrences at 12&#xD;
      months after a single ablative procedure with a laser balloon and without continuous&#xD;
      monitoring with ILR was 74%1.&#xD;
&#xD;
      Assuming that the approach without post-ablative verification of pulmonary vein isolation and&#xD;
      continuous monitoring with ILR can lead to a 60% success rate at 12 months, 80 patients are&#xD;
      required to have an 80% probability to observe a level of 2-code significance of 0.05 in an&#xD;
      exponential model with the log rank test. With an estimated loss of data (patients lost to&#xD;
      follow-up, protocol deviations and incomplete data) of 5%, the total number of patients to be&#xD;
      enrolled is 82.&#xD;
&#xD;
      Subject screening and enrolment will be carried out for approximately 12 months. The study&#xD;
      will continue up to 12 months after last patient enrolment, dependent on the rate of&#xD;
      enrolment and the regulatory timeline (as applicable).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 1, 2019</start_date>
  <completion_date type="Anticipated">November 30, 2021</completion_date>
  <primary_completion_date type="Anticipated">October 30, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Success rate at 1 year</measure>
    <time_frame>12 months after ablation</time_frame>
    <description>Free from AF, atrial tachycardia and flutter documented with ILR or Holter ECG monitorwithout antiarrhythmic drugs.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Procedural and 1-year complications related to the ablation procedure.</measure>
    <time_frame>during the procedure and 12 months after ablation</time_frame>
    <description>Procedural and 1-year complications related to the ablation procedure.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>inducibility of AF after the procedures</measure>
    <time_frame>During the procedure</time_frame>
    <description>programmed atrial stimulation before and after isoproterenol</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AF Burden</measure>
    <time_frame>12 months after ablation</time_frame>
    <description>Assessment of AF burden by holter monitoring or implantable loop recorder</description>
  </secondary_outcome>
  <enrollment type="Anticipated">82</enrollment>
  <condition>Assessment of Safety of Laser Balloon Ablation</condition>
  <condition>Assessment of Procedural Times of Laser Ballon Ablation</condition>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Laser ballon ablation for Pulmonary vein isolation</intervention_name>
    <description>The patients indicated to AF ablation procedure will be treated with laser balloon ablation without verification of electrical isolation of pulmonary veins using implantable loop recorder and/or Holter monitoring</description>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        All patients referred to the Department of Arrhythmology for the management of parosysmal&#xD;
        or persistent AF will be considered for eligibility. A subject, who meets all of the&#xD;
        inclusion criteria, and none of the exclusion criteria, is eligible to participate in this&#xD;
        study.&#xD;
&#xD;
        All subjects enrolled in the clinical study (including those withdrawn from the clinical&#xD;
        study or lost to follow-up) will be accounted for and documented, assigning an&#xD;
        identification code linked to their names, alternative identification or contact&#xD;
        information.&#xD;
&#xD;
        This log will be kept up to date throughout the clinical study by the principal&#xD;
        investigator (PI) or his/her authorized designee. To ensure subject privacy and&#xD;
        confidentiality of data this log must be maintained throughout the clinical study at the&#xD;
        clinical site.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        To participate in this clinical subject, the subject must meet all of the following&#xD;
        inclusion criteria:&#xD;
&#xD;
          -  Age between 18 and 85 years&#xD;
&#xD;
          -  Paroxysmal or persistent AF&#xD;
&#xD;
          -  Patients AF who have indications for the first time ablation procedure according to&#xD;
             the ESC / EHRA recommendations (European Society of Cardiology / European Heart Rhythm&#xD;
             Association).&#xD;
&#xD;
          -  Ability to provide written informed consent for study participation and be willing and&#xD;
             able to comply with the study evaluations and follow up schedule&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        Subjects are not eligible for clinical study participation if they meet any of the&#xD;
        following exclusion criteria:&#xD;
&#xD;
          -  Previous AF ablation procedures&#xD;
&#xD;
          -  Secondary AF due to other causes&#xD;
&#xD;
          -  Hyperthyroidism&#xD;
&#xD;
          -  Left ventricular ejection fraction &lt;30%&#xD;
&#xD;
          -  NYHA class IV&#xD;
&#xD;
          -  Left atrium area &gt; 35 cm2&#xD;
&#xD;
          -  Severe disease of cardiac valves&#xD;
&#xD;
          -  Contraindication to anticoagulant therapy&#xD;
&#xD;
          -  Presence of thrombus in the left atrium&#xD;
&#xD;
          -  Myocardial infarction or unstable angina or recent coronary artery bypass (&lt;6 months)&#xD;
&#xD;
          -  Thoracic surgery for congenital, valvular or aortic disease&#xD;
&#xD;
          -  History of cerebrovascular events&#xD;
&#xD;
          -  Pregnancy&#xD;
&#xD;
          -  Significant comorbidity, such as cancer, severe kidney failure requiring dialysis,&#xD;
             severe obstructive pulmonary disease, cirrhosis, with a life expectancy of less than 2&#xD;
             years&#xD;
&#xD;
          -  Contraindications are present as indicated in the &quot;instructions for use&quot; of the&#xD;
             devices used&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
  </eligibility>
  <overall_official>
    <last_name>Carlo Pappone, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>IRCCS Policlinico San Donato</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Carlo Pappone, MD, PhD</last_name>
    <phone>0252774260</phone>
    <email>carlo.pappone@af-ablation.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Carlo Pappone, MD, PhD</last_name>
    <phone>0252774261</phone>
    <email>carlo.pappone@af-ablation.org</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>IRCCS Policlinico S. Donato</name>
      <address>
        <city>San Donato Milanese</city>
        <state>Milano</state>
        <zip>20097</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Carlo Pappone, MD, PhD</last_name>
      <phone>00390252774260</phone>
      <email>carlo.pappone@af-ablation.org</email>
    </contact>
    <contact_backup>
      <last_name>Carlo Pappone, MD</last_name>
      <phone>00390252774260</phone>
      <email>carlo.pappone@af-ablation.org</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>November 13, 2019</study_first_submitted>
  <study_first_submitted_qc>November 13, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">November 18, 2019</study_first_posted>
  <last_update_submitted>May 18, 2021</last_update_submitted>
  <last_update_submitted_qc>May 18, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 20, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>IRCCS Policlinico S. Donato</investigator_affiliation>
    <investigator_full_name>Carlo Pappone</investigator_full_name>
    <investigator_title>Chief of the Department of Arrhythmology and Electrophysiology</investigator_title>
  </responsible_party>
  <keyword>laser ballon ablation</keyword>
  <keyword>laser ballon</keyword>
  <keyword>pulmonary vein isolation</keyword>
  <keyword>atrial fibrillation</keyword>
  <keyword>AF ablation</keyword>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>August 27, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/42/NCT04165642/Prot_000.pdf</document_url>
    </provided_document>
  </provided_document_section>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

